EGRP News Flash - April 3, 2013
Applications Due June 20 for NCI Provocative Questions Initiative RFAs
The National Cancer Institute (NCI) is sponsoring two Requests for Applications (RFAs) to support research projects to use sound and innovative research strategies to solve specific problems and paradoxes in cancer research as identified by NCI's Provocative Questions (PQs). Researchers are invi ted to submit applications for Research Project Grant (R01) and Exploratory/Developmental Grant (R21) funding mechanisms in four thematic areas. Letters of intent are due May 20, 2013. Applications are due June 20, 2013.
Join a teleconference on Friday, April 12, 2013, 1:00 - 3:00 p.m. E.T., with PQ Program Director Emily J. Greenspan, Ph.D. Ask general questions and obtain information on how to apply for funding. No formal presentation is planned. You can join and exit the call at any point. Dial 1-866-734-3397 and provide participant number 5040755.
The PQ Initiative has assembled a list of important questions to stimulate NCI's research communities to use laboratory, clinical, and population sciences in especially effective and imaginative ways to answer the questions. Researchers are invited to apply for R01 and R21 grants in four thematic areas:
- Unsolved problems in cancer prevention and risk (Group A)
- Perplexing problems in mech anisms of tumor development or recurrence (Group B)
- Improving tumor detection, diagnosis, and prognosis (Group C)
- Problems in cancer therapy and outcomes (Group D)
To be responsive, each application must address a particular scientific problem as defined in the RFAs (and further defined on the Provocative Questions website).
Budgets for R01 applications are not limited but must reflect the actual needs of the proposed project, which may not exceed 4 years. The total project period for R21 applications may not exceed 2 years, and the combined budget of direct costs for an R21 2-year project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Staff in the Epidemiology and Genomics Research Program (EGRP) also recently published commentary in the April 2013 issue of Cancer Epidemiology, Biomarkers and Prevention that discusses leveraging the NCI PQs for cancer epidemiology (PubMed abstract).
Access the NIH Guide for Grants and Contracts for details:
- RFA-CA-12-01 5 (R01 for Group A - Cancer prevention and risk)
- RFA-CA-12-016 (R21 for Group A)
- RFA-CA-12-017 (R01 for Group B - Mechanisms of tumor development and recurrence)
- RFA-CA-12-018 (R21 for Group B)